Q2 Earnings Estimate for OptiNose Issued By HC Wainwright

OptiNose, Inc. (NASDAQ:OPTN) – Investment analysts at HC Wainwright issued their Q2 2025 earnings estimates for OptiNose in a research report issued to clients and investors on Monday, May 19th. HC Wainwright analyst M. Caufield expects that the company will earn ($0.75) per share for the quarter. HC Wainwright currently has a “Neutral” rating and a $9.00 price objective on the stock. The consensus estimate for OptiNose’s current full-year earnings is ($3.22) per share. HC Wainwright also issued estimates for OptiNose’s Q3 2025 earnings at ($0.96) EPS, Q4 2025 earnings at ($1.14) EPS, FY2026 earnings at ($2.91) EPS, FY2027 earnings at ($1.72) EPS, FY2028 earnings at ($0.21) EPS and FY2029 earnings at $1.01 EPS.

A number of other brokerages have also weighed in on OPTN. Lake Street Capital lowered shares of OptiNose from a “buy” rating to a “hold” rating and reduced their price target for the stock from $17.00 to $9.00 in a research note on Thursday, March 20th. Piper Sandler reissued a “neutral” rating and issued a $9.00 target price (down from $15.00) on shares of OptiNose in a research report on Friday, March 21st.

OptiNose Price Performance

Shares of OptiNose stock opened at $9.60 on Wednesday. The company has a market capitalization of $97.22 million, a P/E ratio of -2.29 and a beta of -0.88. OptiNose has a 1-year low of $4.82 and a 1-year high of $20.03. The business’s fifty day moving average price is $8.89 and its two-hundred day moving average price is $7.42.

OptiNose (NASDAQ:OPTN) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.27). The firm had revenue of $18.51 million for the quarter, compared to the consensus estimate of $17.70 million.

Insider Buying and Selling at OptiNose

In other OptiNose news, CEO Ramy A. Mahmoud sold 6,376 shares of OptiNose stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $5.29, for a total value of $33,729.04. Following the completion of the sale, the chief executive officer now directly owns 126,931 shares in the company, valued at $671,464.99. The trade was a 4.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders have sold 8,213 shares of company stock worth $43,643. 2.30% of the stock is currently owned by company insiders.

Institutional Trading of OptiNose

Several large investors have recently added to or reduced their stakes in the business. PenderFund Capital Management Ltd. bought a new position in shares of OptiNose during the 1st quarter valued at $172,000. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new position in OptiNose during the first quarter worth $558,000. Gabelli Funds LLC acquired a new position in OptiNose during the first quarter worth $734,000. Stonepine Capital Management LLC raised its holdings in OptiNose by 34.0% during the first quarter. Stonepine Capital Management LLC now owns 788,647 shares of the company’s stock valued at $7,232,000 after buying an additional 199,990 shares in the last quarter. Finally, Groupe la Francaise acquired a new stake in shares of OptiNose in the first quarter worth about $1,898,000. 85.60% of the stock is owned by institutional investors.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.